The following study has recently been activated for patient enrollment by the University of Illinois Cancer Center Clinical Trials Office (CTO). Please click on the link to learn about the details regarding the study on clinicaltrials.gov. For more information or questions about a study, please email firstname.lastname@example.org or call 312-355-5112.
BTCRC-BRE18-337: Phase 2 Trial with Safety Run-In of Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast Cancers Big Ten Cancer Research Consortium
Sponsor: Kari Wisinski, MD, University of Wisconsin Carbone Cancer Center
Principal Investigator: Oana Danciu, MD